Refine by
Open Heart Articles & Analysis
17 news found
Cloud Hospital with the first team to remove a heart tumor without invasive open heart surgery using the novel AlphaVac catheter. ...
Deborah Heart and Lung Center announces its successful hospital-wide go live with Ivenix, a modern smart infusion pump system. ...
“Currently, there are no transfemoral TAVR devices approved for aortic regurgitation in China; however, some patients with severe aortic regurgitation have to be treated by off-label use of TAVR devices as they are not eligible for open-heart surgery. The Trilogy TM System provides a new treatment option to doctors and brings hope to aortic regurgitation ...
“We applaud the FDA’s decision based on clinical evidence provided to remove the previous barrier to CCM therapy concerned with heart rhythm, opening it up to additional patients in need,” said Jason Spees, President and Chief Commercial Officer of Impulse Dynamics. ...
Each year, ticagrelor is prescribed to millions of cardiovascular patients worldwide to reduce the risk of recurrent heart attack, stroke, or cardiovascular death. Ticagrelor is frequently preferred as first-line therapy in patients presenting to hospitals with an acute coronary syndrome in preparation of percutaneous coronary intervention (PCI) and stent placement. However, up ...
The Trilogy Heart Valve System is the first and only transfemoral TAVR system in the world indicated for the treatment of aortic regurgitation. ...
FDA marketing approval for the intraoperative removal of the key blockbuster antithrombotic drugs Brilinta®, Eliquis® and Xarelto® during open heart surgery to reduce the risk of perioperative bleeding. If successful, we intend to establish DrugSorb-ATR as the go-to, easy-to-use, potential standard of care single treatment for this application in the ...
A summary of the abstracts are as follows: The REMOVE (“Revealing Mechanisms and Investigating Efficiency Of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients with Infective Endocarditis“) investigator initiated randomized, controlled trial enrolled 288 patients with documented infective endocarditis with a EuroSCORE II (European System for Cardiac ...
The current treatment for high surgical risk patients who are not candidates for open-heart surgery consists predominantly of medical management and off-label TAVR. “We are pleased the FDA granted this IDE approval allowing us to continue our pursuit of an aortic regurgitation indication for the Trilogy Heart Valve System,” said John ...
The Trilogy Heart Valve System is the first transfemoral device of its kind to receive CE mark approval for the treatment of both severe symptomatic aortic regurgitation and aortic stenosis. ...
“I am excited Jane is joining us at this pivotal time as we continue to enroll patients into our ALIGN-ARclinical trial and move forward in our efforts to commercialize our TrilogyTM heart valve for the treatment of aortic regurgitation. Herleadership will be critical to the success of JenaValve and our ability to expand patient and physician ...
Together, they observed that current treatments for heart failure are not optimal, are very costly and are invasive for the patient. ...
Patients confronting coronary bifurcation lesions are currently left with only two options: either complex stenting procedures with suboptimal and unpredictable results, or higher risk and more expensive, open-heart surgery. The ABS System is specifically designed to efficiently treat coronary bifurcation lesions with predictable results. ...
Ponikowski P, Anker SD, AlHabib KF et al. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 2014;1:4–25. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the Impact of Heart Failure in the United States. Circ Heart Fail. 2013;6(3):606-19. ...
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. ...
Colibri Heart Valve LLC, a privately held emerging medical device company focused on structural heart applications, announces the formation of a new company called Colorado Therapeutics LLC. ...
Last year's Kohl's Cares scholarship winners included 9-year-old Lily Toomey who has helped the American Heart Association raise $100,000 by sharing her personal story of a congenital heart defect and open heart surgery, 18-year-old Charles Dewey who started a literacy program for homeless children, and Carolyn Houlahan who ...